Lhasa Limited shared knowledge shared progress


This is a library of Lhasa's blog articles. 

  • Collaboration Innovation Working together data sharing
    Clock: less than 5 minutesless than 5 minutes

    Anticipating and supporting the needs of our members

    As a member-based organisation, anticipating and supporting the needs of our members is critical. 

    31 July 2020

  • image portraying data sharing and two ssystems coming together
    Clock: 5 minutes5 minutes

    Comparing CPDB and Lhasa TD50 values in the Lhasa Carcinogenicity Database

    For many years the Carcinogenic Potency Database (CPDB)1, created by Lois Gold and her team, was an important source of long-term carcinogenicity study data. However, as the database had stopped being updated from 2007, Lhasa moved to safeguard the data by providing ongoing access through a freely available interface; the Lhasa Carcinogenicity Database (LCDB)2. The LCDB was released in 2016 and has since been updated with additional data from the National Toxicology Program (NTP)3, increasing the data set to 7,745 studies covering 1,726 chemical substances. A recent update has also facilitated greater ease of access by enabling substructure and similarity-based structure queries.

    08 December 2020

  • MIT Artificial Intelligence AI Machine Learning Technology Knowledge 1170x500px
    Clock: 5 minutes5 minutes

    Effiris: A secondary pharmacology model suite powered by privacy-preserving data sharing

    Artificial Intelligence (AI) has become a powerful force within the pharmaceutical industry, catalysed by the challenging lengthy and costly drug development process. To maximize the impact of AI, it is critical to have access to enough good quality data to allow machine learning algorithms to extract relevant knowledge and produce valuable models.

    21 May 2020

  • Staff sitting together on the floor
    Clock: less than 5 minutesless than 5 minutes

    How Human Resources can positively influence a changing work environment.

    The world of work is changing. My goodness is that an understatement! Never have I truly felt that we are working in what is described as a VUCA (volatile, uncertain, complex and ambiguous) world as much as I do right now.

    18 January 2021

  • Effiris blog image Feb2021
    Clock: less than 5 minutesless than 5 minutes

    How to better anticipate and mitigate adverse drug reactions [an infographic]

    Are you interested in using your data to anticipate and mitigate adverse drug reactions? The Effiris consortium - currently composed of Takeda, GSK and UCB - is working to achieve just that.

    17 February 2021

  • Expert Review Magnifying Glass Results
    Clock: 10 minutes10 minutes

    Human review of in silico predictions of toxicity

    The speed by which models for toxicity prediction can be built and the accuracy with which they can make predictions, have both improved greatly in recent years as a result of advances in technology, mechanistic understanding and access to data.

    21 May 2020

  • expert review 1170px
    Clock: 10 minutes10 minutes

    ICH M7 Expert Review in action: New Expert Review functionality in Nexus 2.3 with worked examples

    In his blog “Human review of in silico predictions of toxicity”, Principal Scientist, Alex Cayley, outlined the reasons why expert review is essential when using in silico tools to assess toxicity, particularly in the ICH M7 use case where expert review of two complementary in silico systems is required [1].

    In this post we discuss how consideration of the user’s journey led to Lhasa tackling the ICH M7 use case with a brand-new automated workflow, now available to Derek and Sarah users in Nexus 2.3. I’ll also show some worked examples of results from the new system.

    16 June 2020

  • Teamwork blog shutterstock
    Clock: less than 5 minutesless than 5 minutes

    It Takes a Team to Build an Adverse Outcome Pathway

    The saying goes, “It takes a village to raise a child”. This sentiment can be translated to the work we do at Lhasa Limited, particularly to the work which we put into building Adverse Outcome Pathways (AOPs). To echo the sentiment in Chris Barber’s previous blog post, The challenge of building QSAR models; it is easy to build an AOP, harder to build a useful AOP, and as for building an AOP you can trust? It takes a team.

    Read about how we are building adverse outcome pathways (AOPs) at Lhasa in this blog post written by Dr. Susanne Stalford, Senior Scientist at Lhasa.


    30 September 2020

  • Lhasa Limited CEO Dr Chris Barber reflects on 2020 and shares plans for the year ahead
    Clock: 5 minutes5 minutes

    Lhasa Limited CEO, Dr. Chris Barber, reflects on 2020 and shares plans for the year ahead

    The global pandemic has undoubtedly had a huge impact on many companies in 2020, Lhasa is no exception.

    14 January 2021

  • Image for solubility purge best practice blog
    Clock: 5 minutes5 minutes

    Lhasa Limited collaborates with industry and regulators to define solubility purge best practice

    Key to the regulatory acceptance of purge arguments is the conservatism within the purge factor scoring system, which for reactivity purge has been demonstrated across a number of publications and is consistently implemented across the pharmaceutical industry through the development of a collective understanding of and how they should be applied.

    Likewise, when volatility purge scoring is relatively simple to understand and apply, particularly using the scoring thresholds originally proposed by Teasdale et al.

    However, through our interactions with Mirabilis users, regulators, and other members of the purge community, it has become increasingly apparent that the same cannot be said of solubility purge scoring. Lhasa have therefore identified the huge value to the community of developing an accepted best practice, incorporating both the application of solubility purge scoring and, where appropriate, provision of a clear justification of the purge factor assigned.

    29 October 2020

  • Vaccine image rendered
    Clock: 5 minutes5 minutes

    Lhasa Limited supports an international initiative in the fight against COVID-19

    Coronaviruses are a large family of viruses which can affect humans or other species and can range anywhere from a mild illness such as the common cold to more severe illnesses such as Severe Acute Respiratory Syndrome (SARS). Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

    25 June 2020

  • Lhasa Limited supports the global challenge of nitrosamine impurity assessment
    Clock: 10 minutes10 minutes

    Lhasa Limited supports the global challenge of nitrosamine impurity assessment

    The recent discovery of N-nitrosamine (nitrosamine) impurities in several marketed pharmaceuticals has led to a requirement for further investigation into nitrosamine mutagenic and carcinogenic activity. Regulatory requirements mean that marketing authorisation holders for human medicines, containing chemically synthesised active substances, must review their medicines for the possible presence of nitrosamines and test all products at risk. Risk-based approaches to prioritise evaluations and subsequent confirmatory testing may be used. These assessments must be completed by October 2020, generating a significant challenge for the pharmaceutical industry.

    13 July 2020

  • Meet Lhasa Limited’s newly appointed Head of Toxicology, Dr. Anax Oliveira
    Clock: 15 minutes15 minutes

    Meet Dr. Anax Oliveira; Lhasa Limited’s newly appointed Head of Toxicology.

    Anax started at Lhasa in September (remotely from Brazil) two months later, Alison checks in to see how things are going. Learn about Anax’s passion for toxicology, career to date, biggest inspiration, plans for his new role at Lhasa and last but not least, where we should all visit in Brazil, in this Q&A session – enjoy!

    30 November 2020

  • Global world conference overseas planet International resized
    Clock: less than 5 minutesless than 5 minutes

    Sharing knowledge is easy: A summary of Lhasa’s India Roadtrip

    There is no perfect formula when it comes to trying to organise any kind of work trip. Normally, you have to engage through a series of mental gymnastics to try and balance semi-quantifiable concepts such as ‘return on investment’ and ‘value’.

    Let’s take ‘value’ for instance. Is the value of the trip based on a new sale? The time spent out of the office? Establishing a personal contact to secure existing business? Ensuring that the product that you’re supporting is used and understood to the maximum capacity?

    Now balance that with travelling halfway across the planet, rather than a quick hop on the Eurostar.

    Read more about our trip to India earlier this year.

    15 June 2020

  • Kaptis blog imagery
    Clock: 5 minutes5 minutes

    The Application of Adverse Outcome Pathways (AOPs) for Risk Assessment (A Webinar Summary)

    AOPs have the potential to be very powerful for the contextualisation of alternative assays and consequently for the management of alternative testing strategies. Read about what Lhasa is doing in this area in this blog piece written by Alun Myden, Senior Scientist at Lhasa.

    03 July 2020

  • Computer Software development Models QSAR In Silico 1170x500px
    Clock: 5 minutes5 minutes

    The challenge of building QSAR models

    Building QSAR models is easy. Building useful QSAR models is harder. Building QSAR models you can trust – well that can be really challenging – and this is where a lot of Lhasa’s effort is dedicated – creating models that can be used with confidence to make big decisions – such as those made during a regulatory submission that can protect human safety through exposure of a compound or its impurities! 

    19 May 2020

  • Collaboration Data Sharing Knowledge 1170x500px
    Clock: less than 5 minutesless than 5 minutes

    The Importance of Pre-competitive Collaborations

    Throughout the history of science, progression has relied upon the generation of new knowledge and  then building on that knowledge in order to gain even greater insight. In order to progress, this knowledge needs to be shared as widely as possible.

    26 June 2020

  • Richard Williams 1170x500
    Clock: less than 5 minutesless than 5 minutes

    The Richard Williams Memorial Award

    An award honouring the scientific contributions and memory of Dr. Richard Williams, has been set up to support early career investigators within industry. Supported by the Industrial Genotoxicology Group (IGG), The Richard Williams Memorial Award will sponsor one individual a year to attend and present at the United Kingdom Environmental Mutagen Society (UKEMS) meeting.

    26 July 2020

  • listening member needs people connecting sharing ideas understanding 1170x500
    Clock: less than 5 minutesless than 5 minutes

    Understanding the users' needs

    Building software and providing services that meet the needs of the user was central to the unique way in which Lhasa was founded and is still very much at the core of how we operate.

    11 December 2020

  • Handshake
    Clock: 15 minutes15 minutes

    We can apply a lot about how we trust one another when building and using in silico models

    One of the most important ingredients for an effective team is trust, and a critical phase of team building is starting to develop that sense of trust – to be strong has to be earnt and regularly reinforced; it is rarely simply given! The same is true when using in silico models and by mirroring the natural approaches – the intuitive tests that we apply either consciously or subconsciously - we can understand how and when a model can be effectively used.

    15 May 2020

© 2021 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).

Apart from the free survey software, we also have access to QuestionPro's free survey templates . We've found many of them useful and powerful to collect insights from various stakeholders of our organization.